Zhejiang Starry Pharmaceutical Co.,Ltd. (SHA:603520)
China · Delayed Price · Currency is CNY 10.38
+0.03 (0.29%)
Feb 4, 2026, 3:00 PM CST
SHA:603520 Revenue
Zhejiang Starry Pharmaceutical had revenue of 447.26M CNY in the quarter ending September 30, 2025, a decrease of -5.66%. This brings the company's revenue in the last twelve months to 2.39B, up 0.89% year-over-year. In the year 2024, Zhejiang Starry Pharmaceutical had annual revenue of 2.35B with 7.02% growth.
Revenue (ttm)
2.39B
Revenue Growth
+0.89%
P/S Ratio
1.90
Revenue / Employee
1.36M
Employees
1,754
Market Cap
4.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.35B | 154.24M | 7.02% |
| Dec 31, 2023 | 2.20B | 64.75M | 3.04% |
| Dec 31, 2022 | 2.13B | 131.32M | 6.57% |
| Dec 31, 2021 | 2.00B | 632.83M | 46.29% |
| Dec 31, 2020 | 1.37B | 58.25M | 4.45% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jinling Pharmaceutical Company | 3.13B |
| Tianjin Tianyao Pharmaceuticals | 2.87B |
| Yabao Pharmaceutical Group | 2.27B |
| Guizhou Sanli Pharmaceutical Co.,Ltd | 1.74B |
| Ningbo Menovo Pharmaceutical | 1.54B |
| Zhuhai Rundu Pharmaceutical | 1.19B |
| Tibet Weixinkang Medicine | 1.17B |
| LanZhou Foci Pharmaceutical | 895.75M |